Sarcinelli Michelle Alvares, Martins da Silva Thalita, Artico Silva Andressa Daniele, Ferreira de Carvalho Patricio Beatriz, Mendes de Paiva Flávia Costa, Santos de Lima Raissa, Leal da Silva Manuela, Antunes Rocha Helvécio Vinícius
Laboratório de Micro e Nanotecnologia, Instituto de Tecnologia Em Fármacos (Farmanguinhos), Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, 21040-361, Brazil.
Rede Rio de Inovação em Nanossistemas para a Saúde - NanoSAÚDE/ FAPERJ, Rio de Janeiro, RJ, Brazil.
J Drug Deliv Sci Technol. 2021 Jun;63:102430. doi: 10.1016/j.jddst.2021.102430. Epub 2021 Feb 24.
The outbreak of the disease caused by the new coronavirus (COVID-19) has been affecting society's routine and its patterns of interaction worldwide, in addition to the impact on the global economy. To date, there is still no clinically effective treatment for this comorbidity, and drug repositioning might be a good strategy considering the established clinical safety profile. In this context, since COVID-19 affects the respiratory tract, a promising approach would be the pulmonary drug delivery.
Identify repurposing drug candidates for the treatment of COVID-19 based on the data of ongoing clinical trials and in silico studies and also assess their potential to be applied in formulations for pulmonary administration.
A integrative literature review was conducted between June and July 2020, by extracting the results from Clinical Trials, PubMed, Web of Science and Science Direct databases.
By crossing the results obtained from diverse sources, 21 common drugs were found, from which only 4 drugs presented studies of pulmonary release formulations, demonstrating the need for greater investment and incentive in this field.
Even though the lung is a target that facilitates viral infection and replication, formulations for pulmonary delivery of suitable drugs are still lacking for COVID-19 treatment. However, it is indisputable that the pandemic constitutes a concrete demand, with a profound impact on public health, and that, with the appropriate investments, it will give the pharmaceutical industry an opportunity to reinforce the pulmonary delivery field.
新型冠状病毒（COVID-19）引发的疾病爆发不仅影响了全球经济，还在全球范围内影响着社会日常及互动模式。迄今为止，针对这种合并症仍没有临床有效的治疗方法，考虑到已确立的临床安全性，药物重新定位可能是一种不错的策略。在这种背景下，由于COVID-19会影响呼吸道，肺部给药可能是一种很有前景的方法。
基于正在进行的临床试验数据和计算机模拟研究，确定用于治疗COVID-19的重新利用药物候选物，并评估它们应用于肺部给药制剂的潜力。
2020年6月至7月进行了一项综合文献综述，通过从临床试验、PubMed、科学网和科学直投数据库中提取结果。
通过交叉来自不同来源的结果，发现了21种常用药物，其中只有4种药物有肺部释放制剂的研究，这表明该领域需要更多的投资和激励。
尽管肺部是促进病毒感染和复制的靶点，但用于COVID-19治疗的合适药物的肺部给药制剂仍然缺乏。然而，无可争议的是，这场大流行构成了一项具体需求，对公共卫生产生了深远影响，并且通过适当的投资，它将为制药行业提供一个加强肺部给药领域的机会。
